Study title: A randomized, double-blind, parallel group study to determine the effective duration (6, 8, 10 or 12 weeks) and safety of LamisilÒ (tablets) given once daily to patients with tinea capitis due to Microsporum species (mainly M. canis).
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Bacterial Infections and Mycoses [C01] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: TERBINAFINE | |||||
ATC code: D01BA02 | |||||
Document link: SFO327 T202MR.xls | |||||
Document date: 2011-09-14 | |||||
Study number: SFO327T202 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |